10 Stock With Eye-Popping Gains; 5 Are on Fresh Highs

Page 9 of 9

1. ImmunityBio Inc. (NASDAQ:IBRX)

ImmunityBio extended its winning streak to a 10th consecutive day on Thursday, soaring 30.79 percent to close at $3.95 apiece, as investors loaded portfolios after achieving a 700 percent jump in preliminary revenues from Anktiva for the full-year 2025.

During the period, ImmunityBio Inc. (NASDAQ:IBRX) said that it registered $113 million in revenues from Anktiva amid strong demand. Anktiva is the first FDA-approved immunotherapy for non-muscle invasive bladder cancer.

In the fourth quarter alone, ImmunityBio Inc. (NASDAQ:IBRX) posted $38.3 million in net revenues, marking a 431 percent increase from the same period last year.

“ImmunityBio continues to see increased sales momentum supporting a trend of increases quarter-over-quarter with a 54 percent quarter over quarter unit volume growth rate during FY 2025,” it said.

In other recent news, ImmunityBio Inc. (NASDAQ:IBRX) has secured the approval of the Saudi Food and Drug Administration to sell and market Anktiva, in combination with an immune checkpoint inhibitor, in Saudi Arabia.

“This approval represents a significant step forward for lung cancer patients in the Kingdom of Saudi Arabia and a meaningful milestone that we hope will pave the way toward additional approvals across a region where lung cancer claims far too many lives each year,” said Executive Chairman Patrick Soon-Shiong.

While we acknowledge the potential of IBRX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than IBRX and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge fund investor letters by entering your email below.

Page 9 of 9